Loading...

Algernon Pharmaceuticals Inc.

AGN.CNCNQ
Healthcare
Biotechnology
CA$0.10
CA$0.00(0.00%)

Algernon Pharmaceuticals Inc. AGN.CN Peers

See (AGN.CN) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
AGN.CNCA$0.10N/A3.1M3.17CA$0.03N/A
BLU.TOCA$19.48-0.10%2.5B-20.29-CA$0.96N/A
MMED.NECA$14.90+9.48%1.1B-4.50-CA$3.31N/A
FRX.TOCA$11.11+3.25%306.8M-15.43-CA$0.72N/A
DRUG.CNCA$38.83+1.46%275M-194.15-CA$0.20N/A
CYBN.NECA$10.81-3.48%227.3M-2.18-CA$4.96N/A
EPRX.TOCA$5.70+6.54%204.3M-5.48-CA$1.04N/A
MSCL.TOCA$0.52-3.70%91.7M2.08CA$0.25N/A
ONC.TOCA$0.87+6.10%77.3M-2.12-CA$0.41N/A
MSET.CNCA$0.74-1.33%75M-12.33-CA$0.06N/A
Showing 1 to 10 of 59 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

AGN.CN vs BLU.TO Comparison

AGN.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AGN.CN stands at 3.1M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, AGN.CN is priced at CA$0.10, while BLU.TO trades at CA$19.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AGN.CN currently has a P/E ratio of 3.17, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, AGN.CN's ROE is +0.15%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, AGN.CN is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.CN.

Stock Price Comparison

Loading...

Frequently Asked Questions